Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Accumulated Depreciation (2022 - 2025)

Historic Accumulated Depreciation for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $1.7 million.

  • BioXcel Therapeutics' Accumulated Depreciation rose 2126.32% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 2126.32%. This contributed to the annual value of $1.5 million for FY2024, which is 2590.11% up from last year.
  • Per BioXcel Therapeutics' latest filing, its Accumulated Depreciation stood at $1.7 million for Q3 2025, which was up 2126.32% from $1.7 million recorded in Q2 2025.
  • BioXcel Therapeutics' Accumulated Depreciation's 5-year high stood at $1.7 million during Q3 2025, with a 5-year trough of $679000.0 in Q1 2022.
  • Its 4-year average for Accumulated Depreciation is $1.2 million, with a median of $1.2 million in 2023.
  • As far as peak fluctuations go, BioXcel Therapeutics' Accumulated Depreciation soared by 4212.08% in 2023, and later surged by 2126.32% in 2025.
  • BioXcel Therapeutics' Accumulated Depreciation (Quarter) stood at $885000.0 in 2022, then surged by 34.8% to $1.2 million in 2023, then grew by 25.9% to $1.5 million in 2024, then grew by 15.05% to $1.7 million in 2025.
  • Its Accumulated Depreciation stands at $1.7 million for Q3 2025, versus $1.7 million for Q2 2025 and $1.6 million for Q1 2025.